Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD

8.7567  -0.67 (-7.14%)

Fundamental Rating

3

Overall ZVRA gets a fundamental rating of 3 out of 10. We evaluated ZVRA against 193 industry peers in the Pharmaceuticals industry. ZVRA may be in some trouble as it scores bad on both profitability and health. ZVRA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZVRA has reported negative net income.
In the past year ZVRA has reported a negative cash flow from operations.
In the past 5 years ZVRA always reported negative net income.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -53.26%, ZVRA is not doing good in the industry: 61.66% of the companies in the same industry are doing better.
ZVRA's Return On Equity of -224.24% is on the low side compared to the rest of the industry. ZVRA is outperformed by 71.50% of its industry peers.
Industry RankSector Rank
ROA -53.26%
ROE -224.24%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Gross Margin of ZVRA (84.42%) is better than 90.67% of its industry peers.
The Profit Margin and Operating Margin are not available for ZVRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZVRA has been increased compared to 1 year ago.
The number of shares outstanding for ZVRA has been increased compared to 5 years ago.
Compared to 1 year ago, ZVRA has a worse debt to assets ratio.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ZVRA has an Altman-Z score of -2.53. This is a bad value and indicates that ZVRA is not financially healthy and even has some risk of bankruptcy.
ZVRA has a Altman-Z score (-2.53) which is comparable to the rest of the industry.
ZVRA has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
ZVRA has a Debt to Equity ratio of 1.46. This is in the lower half of the industry: ZVRA underperforms 75.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z -2.53
ROIC/WACCN/A
WACC10.27%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.02 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Current ratio (3.02) which is comparable to the rest of the industry.
ZVRA has a Quick Ratio of 2.93. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA has a Quick ratio (2.93) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.93
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

ZVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.22%.
The Revenue has grown by 44.90% in the past year. This is a very strong growth!
The Revenue has been growing by 12.96% on average over the past years. This is quite good.
EPS 1Y (TTM)-42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85%
Revenue 1Y (TTM)44.9%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%495.65%

3.2 Future

ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.22% yearly.
ZVRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 78.42% yearly.
EPS Next Y142.27%
EPS Next 2Y51.49%
EPS Next 3Y40.66%
EPS Next 5Y28.22%
Revenue Next Year354.75%
Revenue Next 2Y184.23%
Revenue Next 3Y129.09%
Revenue Next 5Y78.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZVRA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 13.13, the valuation of ZVRA can be described as correct.
ZVRA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ZVRA is cheaper than 79.27% of the companies in the same industry.
ZVRA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.78.
Industry RankSector Rank
PE N/A
Fwd PE 13.13
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 40.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.49%
EPS Next 3Y40.66%

More info and screens

0

5. Dividend

5.1 Amount

ZVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (8/14/2025, 11:37:59 AM)

8.7567

-0.67 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners63.31%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change-14.43%
Market Cap478.82M
Analysts84.29
Price Target24.33 (177.84%)
Short Float %9.2%
Short Ratio5.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.57%
Min EPS beat(2)-67.34%
Max EPS beat(2)68.49%
EPS beat(4)1
Avg EPS beat(4)-16.97%
Min EPS beat(4)-67.34%
Max EPS beat(4)68.49%
EPS beat(8)3
Avg EPS beat(8)-8.84%
EPS beat(12)3
Avg EPS beat(12)-21.64%
EPS beat(16)5
Avg EPS beat(16)-14.2%
Revenue beat(2)2
Avg Revenue beat(2)25.11%
Min Revenue beat(2)17.95%
Max Revenue beat(2)32.28%
Revenue beat(4)3
Avg Revenue beat(4)6.19%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)22.76%
Revenue beat(12)6
Avg Revenue beat(12)9.85%
Revenue beat(16)8
Avg Revenue beat(16)9%
PT rev (1m)6.37%
PT rev (3m)7.05%
EPS NQ rev (1m)33.2%
EPS NQ rev (3m)129.26%
EPS NY rev (1m)0%
EPS NY rev (3m)450.88%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)6.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.13
P/S 11.8
P/FCF N/A
P/OCF N/A
P/B 11.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)0.67
Fwd EY7.62%
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.74
BVpS0.75
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.26%
ROE -224.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.42%
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.18%
Cap/Sales 15.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 2.93
Altman-Z -2.53
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85%
EPS Next Y142.27%
EPS Next 2Y51.49%
EPS Next 3Y40.66%
EPS Next 5Y28.22%
Revenue 1Y (TTM)44.9%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%495.65%
Revenue Next Year354.75%
Revenue Next 2Y184.23%
Revenue Next 3Y129.09%
Revenue Next 5Y78.42%
EBIT growth 1Y-26.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.79%
EBIT Next 3Y40.08%
EBIT Next 5Y32.81%
FCF growth 1Y-251.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-221.13%
OCF growth 3YN/A
OCF growth 5YN/A